Announcement Of The Pathway Transformation Fund Outcomes

Posted on 7 June 2021 (Permalink)

The Rapid Uptake Products (RUP) programme supports stronger adoption and spread of NICE approved proven innovations targeting clinical priorities as set out in the NHS Long Term Plan.

The 2021/22 supported RUPs are: Lipid Management, a NICE-endorsed clinical pathway to help reduce cholesterol; Asthma Biologics, a treatment for severe Asthma; FeNO testing, which aids diagnosis of Asthma; and Tamoxifen as a preventative treatment for breast cancer. Funding has to date been made available for the first three RUPs and organisations will have the opportunity to apply for funding for Tamoxifen projects from June onwards.

For the latest update visit: